Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 4/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31750319 | 1.00 | SMYD3 (0.59) | SMYD3ALOX5PARP1ALOX15HSD17B10 | |
| SCHEMBL2238303 | 1.00 | SMYD3 (0.59) | SMYD3ALOX5PARP1ALOX15HSD17B10 | |
| SCHEMBL12362558 | 1.00 | SMYD3 (0.59) | SMYD3ALOX5PARP1ALOX15HSD17B10 | |
| SCHEMBL8029156 | 0.89 | PARP1 (0.51) | SMYD3ALOX5PARP1ALOX15HSD17B10 | |
| SCHEMBL34474521 | 0.85 | ALOX5 (0.54) | SMYD3ALOX5PARP1ALOX15HSD17B10 | |
| SCHEMBL2882943 | 0.84 | SMYD3 (0.62) | SMYD3ALOX5PARP1USP2GAA | |
| SCHEMBL2818354 | 0.84 | SMYD3 (0.62) | SMYD3ALOX5PARP1USP2GAA | |
| SCHEMBL19691113 | 0.84 | SMYD3 (0.62) | SMYD3PARP1USP2GAAPDE3B | |
| SCHEMBL24124659 | 0.83 | SMYD3 (0.58) | SMYD3PARP1USP2GAAPDE3B | |
| SCHEMBL16792512 | 0.83 | SMYD3 (0.62) | SMYD3PARP1HSD17B10USP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081521-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LTD (IN) | 2025-12-10 | — | — | EP | disclosed |
| CN-115605476-B | Substituted tricyclic compounds | 鲁宾有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2023-12-21 | — | — | US | disclosed |
| US-20230119316-A1 | Substituted Tricyclic Compounds | LUPIN LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| CN-115605476-A | Substituted tricyclic compounds | 鲁宾有限公司（IN） | 2023-01-13 | — | — | CN | disclosed |
| EP-4081521-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | Lupin Limited (IN) | 2022-11-02 | — | — | EP | disclosed |
| CN-115028619-A | SMYD inhibitors | EPIZYME股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| CN-107072205-B | SMYD inhibitors | EPIZYME股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-1681811-A | Azolidinone-vinyl fused-benzene derivatives | APPLIED RESEARCH SYSTEMS (AN) | 2005-10-12 | — | — | CN | disclosed |
| EP-1015437-B1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AG (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| CN-1060769-C | 1,4-benzoxazine derivatives, pharmaceutical composition containing the same and use thereof | KENEBO LTD (JP) | 2001-01-17 | — | — | CN | disclosed |
| EP-1015437-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-07-05 | — | — | EP | disclosed |
| EP-0719766-B1 | 1,4-Benzoxazine derivative, pharmaceutical composition containing the same and use thereof | KANEBO LTD (JP) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999012915-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-03-18 | — | — | WO | disclosed |
| US-5597820-A | CARDIOVASCULAR DISORDERS | KANEBO, LTD. (JP) | 1997-01-28 | — | — | US | disclosed |
| CN-1130183-A | 1,4-benzoxazine derivatives, pharmaceutical composition containing the same and use thereof | KANEBO LTD (JP) | 1996-09-04 | — | — | CN | disclosed |
| EP-0719766-A1 | 1,4-Benzoxazine derivative, pharmaceutical composition containing the same and use thereof | KANEBO LTD. (JP) | 1996-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | SMYD3 442/4885ALOX5 4567/4885PARP1 794/4885 |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | SMYD3 442/4885ALOX5 4567/4885PARP1 794/4885 |
| US-20230119316-A1 | Substituted Tricyclic Compounds | SOS1, RSU1, KSR1 | SMYD3 4257/4885ALOX5 4010/4885PARP1 3524/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885ALOX5 3891/4885PARP1 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.